Balaxi Pharmaceuticals Limited is a branded IPR-based pharmaceutical Company focusing on frontier markets, with a vast and growing portfolio of drugs across multiple therapeutic segments. Its markets extend across the continents of Americas, Africa and the Caribbean islands. It is a dynamic and responsible company, with a rich and growing portfolio of branded and generic medicines and consumer products.

Business area of the company

The company is engaged in the business of international wholesale trading of Pharmaceuticals, Builders Hardware and FMCG products

History and Milestones

2003-07

Commenced Pharmaceutcal business by supplying white labeled products to customers in Africa.
Sourcing was from WHO GMP certified plants based in India.

2008-10

Created frontend presence for its Pharmaceutical Business by setting up 1st wholesale depot in Angola in 2008.

2011-13

Started sourcing pharmaceutical from WHO GMP certified manufacturers in China by setting up an office in China in 2011.
Opened first wholesale depot for its ancillary business in Angola.

2014-16

In 2014, the group expanded its pharmaceutical business in Angola by setting up its 12th wholesale depot and a central distribution warehouse.
Made in-roads in Dominican Republic pharmaceutical market, submitted technical dossiers for securing product registrations and opened a central distribution warehouse.

2017-19

Set-up central distribution warehouse in Guatemala marking the entry of Balaxi into its third geography.
Leveraged the vast on-ground infrastructure in Angola by entering branded consumer goods products business in 2019.

2020

Submitted several technical dossiers of Pharmaceutical products in EL Salvador and Honduras for product registrations.

Market Cap	447 Cr	ROE	32.2%
P/E Ratio(TTM)	0.0	EPS(TTM)	0.0
P/B Ratio	3.0	Dividend Yield	0.0%
Industry P/E	92.8	Book Value	144.6
		Face Value	10.0

Fundamentals